Eg5 was found to be overexpressed in various proliferative tissues, and was detected in many cancers, such as lung, pancreatic, breast, ovarian, bladder cancers and leukaemia, which renders Eg5 a potential target for developing novel inhibitors as anti-cancer agents [5, 6]. This evidence concerns the gene KIF11 and urinary bladder carcinoma.